Hard to believe? Well, a new ranking suggests the Swiss drugmaker will become the biggest of the big by 2014 thanks to "surging" demand for various its cancer meds, such Avastin, Mircera and Herceptin, according to
, adding that buying up all of Genentech would only solidify its position.
The big loser? Pfizer, not surprisingly, since it faces patent expirations on so many big drugs, namely Lipitor, Norvasc and Viagra. We realize, by the way, that this list has been circulating for a couple of days, but we enjoy speculation as much as anyone.